BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32933570)

  • 1. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization.
    Yang Y; Luo J; Chen X; Yang Z; Mei X; Ma J; Zhang Z; Guo X; Yu X
    J Exp Clin Cancer Res; 2020 Sep; 39(1):188. PubMed ID: 32933570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
    Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
    Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
    Goel S; DeCristo MJ; McAllister SS; Zhao JJ
    Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
    Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
    Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
    Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibition triggers anti-tumour immunity.
    Goel S; DeCristo MJ; Watt AC; BrinJones H; Sceneay J; Li BB; Khan N; Ubellacker JM; Xie S; Metzger-Filho O; Hoog J; Ellis MJ; Ma CX; Ramm S; Krop IE; Winer EP; Roberts TM; Kim HJ; McAllister SS; Zhao JJ
    Nature; 2017 Aug; 548(7668):471-475. PubMed ID: 28813415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Teh JLF; Aplin AE
    Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
    Roberts PJ; Kumarasamy V; Witkiewicz AK; Knudsen ES
    Mol Cancer Ther; 2020 Aug; 19(8):1575-1588. PubMed ID: 32546660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
    Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
    J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Cycle Therapeutics Come of Age.
    Ingham M; Schwartz GK
    J Clin Oncol; 2017 Sep; 35(25):2949-2959. PubMed ID: 28580868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
    Knudsen ES; Witkiewicz AK
    Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.